The Chinese government is dedicated to fostering sustainable innovation within the public healthcare and pharmaceutical sectors to safeguard public interests. However, current policies governing the pharmaceutical industry have inadequately addressed critical issues related to stakeholder dynamics and sustainable innovation performance. This study investigates how policy reform can enhance the dynamic relationships among stakeholders in China's public healthcare system, aiming to devise actionable and detailed tasks while minimizing conflicts to encourage sustainable innovation. This research presents the findings of in-depth interviews conducted with 50 participants from key stakeholders in China's public health sector, including government officials, hospital representatives, executives from state-owned pharmaceutical companies, and healthcare professionals. The findings offer valuable insights for practitioners, policymakers, and academics regarding the application of social exchange elements—such as power, trust, reputation, reciprocity, and commitment—in understanding the necessity of integrating relationship dynamics into policy design and reform within the supply chain network, all while protecting public interests. Furthermore, the study emphasizes the shortcomings of the existing policy framework and presents compelling arguments for reforms that actively involve key stakeholders in the public healthcare and pharmaceutical industries.
扫码关注我们
求助内容:
应助结果提醒方式:
